Biophytis

Executive Summary

Biophytis is a French biotechnology company pioneering therapies to extend healthy longevity, leveraging its AI-accelerated research platform to discover novel drug candidates. The company's lead program, BIO101 (20-hydroxyecdysone), targets sarcopenia, a debilitating age-related muscle loss condition with no approved therapies. Currently in Phase 3 clinical development, BIO101 has shown promise in earlier trials by improving muscle mass and function. Biophytis aims to address the significant unmet need in geriatric health, positioning itself as a leader in the longevity space. With a private structure and a focus on a high-impact indication, the company is poised for potential value inflection upon successful trial completion and regulatory engagement. The platform's versatility also enables expansion into other aging-related diseases, though near-term value hinges primarily on the sarcopenia program.

Upcoming Catalysts (preview)

• H2 2026Phase 3 top-line results for BIO101 in sarcopenia60% success
• 2027Regulatory submission (FDA/EMA) for BIO10150% success
• 2026Partnership or licensing deal for non-sarcopenia indications40% success